Short Interest in Takeda Pharmaceutical Company Limited (NYSE:TAK) Drops By 24.4%

Takeda Pharmaceutical Company Limited (NYSE:TAK - Get Free Report) was the recipient of a large drop in short interest in January. As of January 15th, there was short interest totalling 3,710,000 shares, a drop of 24.4% from the December 31st total of 4,910,000 shares. Based on an average daily volume of 1,710,000 shares, the days-to-cover ratio is presently 2.2 days.

Takeda Pharmaceutical Price Performance

Shares of Takeda Pharmaceutical stock traded down $0.14 during midday trading on Monday, hitting $13.26. 1,692,360 shares of the company traded hands, compared to its average volume of 2,069,611. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. Takeda Pharmaceutical has a 12 month low of $12.57 and a 12 month high of $15.08. The stock has a market cap of $42.18 billion, a price-to-earnings ratio of 33.14, a PEG ratio of 0.23 and a beta of 0.51. The firm's fifty day moving average price is $13.31 and its 200-day moving average price is $13.89.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, sell-side analysts forecast that Takeda Pharmaceutical will post 1.64 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Versant Capital Management Inc purchased a new stake in shares of Takeda Pharmaceutical during the 4th quarter valued at $26,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Takeda Pharmaceutical in the 3rd quarter valued at about $40,000. BNP Paribas Financial Markets increased its position in shares of Takeda Pharmaceutical by 416.0% in the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company's stock valued at $46,000 after acquiring an additional 2,596 shares during the period. Smithfield Trust Co boosted its stake in shares of Takeda Pharmaceutical by 76.9% during the 3rd quarter. Smithfield Trust Co now owns 3,428 shares of the company's stock valued at $49,000 after purchasing an additional 1,490 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in shares of Takeda Pharmaceutical in the 3rd quarter worth about $52,000. 9.17% of the stock is owned by institutional investors and hedge funds.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.